
Supplemental Figure 1. MSK PONV Antiemetic Guideline.



MSK, Memorial Sloan Kettering Cancer Center; PONV, postoperative nausea and vomiting.

# Supplemental Figure 2. Discharge Scoring Tool

# MSK Post-Anesthetic Discharge Scoring Tool (Adult)

#### **LEVEL OF CONSCIOUSNESS:**

- 2 = Awake , easily arousable
- 1 = frequently drowsy, drifts to sleep, but arousable to stimuli
- 0 = Minimal or no response to stimuli

#### **OXYGEN SATURATION:**

- 2 = O2 Sat ≥ 92% on room air
- 1 = O2 Sat ≥ 92% with Nasal Canula, BiPAP, Blow-by, CPAP, Face tent, RSV hood, or Trach collar regardless of amount of oxygen delivery requirement
- 0 = O2 Sat < 92% or any patient on simple facemask, high flow facemask, heliox, t-piece, Optiflow, non-rebreather, or mechanical assistance

### HEMODYNAMIC STABILITY:

- 2 = baseline SBP + / 10 mmHg
- 1 = baseline SBP + / 11 to 30 mmHg
- 0 = baseline SBP + / >30 mmHg

## **POST-OPERATIVE /PROCEDURE PAIN:**

Numeric or Wong Baker pain scale

- 2 = acceptable pain level
- 0 = unacceptable pain level

## If FLACC or CPOT scale

- 2 = score of 0-2
- 1 = score of 3-6
- 0 = score of 7 or greater

# **NAUSEA/VOMITING:**

- 2 = none or mild nausea with no active vomiting
- 1 = none or mild nausea with vomiting; moderate nausea with no vomiting
- 0 = moderate nausea with vomiting; Severe nausea with or without vomiting; Or unable to assess nausea.

#### Supplemental Figure 3. Compliance rates with each ERAS measure by quarter.



Examples of interactive, real-time compliance dashboards for each procedure over the study period. Dashboard filters (not shown) permit selection of a number of criteria, including time period, surgical service, procedures, patient class, surgery location, and outcome parameters of interest. Proportion of eligible cases which achieved the given ERAS measure within each quarter are presented. Note, case numbers by procedure vary from Table 2 because of slight differences in procedure identification queries used and due to inclusion of patients with multiple procedures in dashboard that were excluded from primary analysis. APAP, Acetaminophen. Dexam, dexamethasone. Gbp, gabapentin. Ondan, ondansetron. PNB, peripheral nerve block. TIVA, total intravenous anesthesia. Dexmed, dexmedetomidine. Lido 4%, 4% lidocaine, PropofolInf, Propofol Infusion. ERAS, enhanced recovery after surgery.

**Supplemental Table 1. Compliance rates by surgical procedure.** Average compliance over the study period. Patients were excluded if they had clinical contraindications or refused the intervention. Data presented as n (%).

Characteristic	Mastectomy, n = 2965	Minimally invasive hysterectomy, n = 1099	Thyroidectomy, n = 680	Minimally invasive prostatectomy, n = 1976
Preoperative aprepitant	443 (76%)	153 (74%)	72 (75%)	
Preoperative gabapentin	2262 (93%)	674 (84%)	n/a	1128 (93%)
Excluded	528	299		769
Paravertebral nerve block	1871 (84%)	n/a	n/a	n/a
Excluded	742			
Dexamethasone	2841 (96%)	1086 (99%)	577 (85%)	1946 (98%)
Excluded	6	0	2	0
Ondansetron	2824 (95%)	1070 (97%)	653 (96%)	1920 (97%)
Excluded	6	0	2	0
Acetaminophen	2797 (94%)	1036 (94%)	647 (95%)	1881 (95%)
Ketorolac	1357 (46%)	891 (82%)	n/a	1502 (83%)
Excluded	29	17		174
Lidocaine	n/a	n/a	315 (46%)	n/a
Excluded			0	

# **Supplemental Table 2. Quality indicators by surgical procedure.** Data are presented as median (interquartile range) or n (%).

Characteristic	Mastectomy, n = 2965	Minimally invasive hysterectomy, n = 1099	Thyroidectomy, n = 680	Minimally invasive prostatectomy, n = 1976
Time to first ambulation (h)	5.7 (4.4, 9.0)	5.1 (4.0, 6.5)	5.1 (3.6, 7.1)	5.3 (4.4, 6.5)
Unknown	1183	473	321	690
PACU length of stay (h)	19.5 (17.5, 21.7)	17.6 (7.8, 20.8)	19.6 (17.1, 21.5)	20.0 (17.4, 21.7)
Reoperation	95 (3.2%)	1 (< 0.1%)	3 (0.4%)	1 (< 0.1%)
Transferred to hospital	52 (1.8%)	13 (1.2%)	10 (1.5%)	32 (1.6%)
Readmitted within 30 days	94 (3.2%)	31 (2.8%)	6 (0.9%)	43 (2.2%)
Urgent care visit within 30 days	201 (6.8%)	85 (7.7%)	21 (3.1%)	150 (7.6%)

PACU, post-anesthesia care unit.